Lastest Report on Gastrointestinal Therapeutics Market 2019

1
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent ExpiriesbyMarketsandMarkets

• Explore all reports for Gastrointestinal
  therapeutics market _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/therapeutics/gastrointestinal
  -therapeutics .

2
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• GBI Research, the leading business intelligence
  provider, has released its latest research,
  Gastrointestinal Therapeutics in Major Developed
  Markets to 2019 New Drug Approvals and Promising
  Pipeline to Counter Declines from Patent
  Expiries, which provides insights into three
  gastrointestinal therapeutic indications in the
  major developed markets of the US, the UK,
  France, Germany, Italy, Spain, Japan and Canada.
  The report provides an in-depth analysis of three
  gastrointestinal therapeutics markets, namely
  Irritable Bowel Syndrome (IBS), Ulcerative
  Colitis (UC) and Crohns Disease (CD). The report
  provides an estimation of market size for 2012,
  along with market forecast until 2019. It also
  covers disease epidemiology, treatment
  algorithms, treatment patterns, in-depth analysis
  of the pipeline, and deal analysis for these
  three gastrointestinal indications.
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis carried
  out by GBI Researchs team of industry experts.
• Request a Sample _at_ http//www.rnrmarketresearch.co
  m/contacts/request-sample?rname145683 .

3
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• Scope
• The report analyzes treatment usage patterns,
  market characterization, pipeline analysis and
  key licensing and co-development deals for the
  IBS, UC and CD indications in the major developed
  markets of the US, the UK, France, Germany,
  Italy, Spain, Japan and Canada.
• Disease overview and treatment usage patterns
• Market size and forecast for IBS, UC and CD in
  major developed markets from 2012 to 2019
• Major marketed products for the indication types
  covered
• In-depth pipeline analysis for IBS, UC and CD
• Key drivers and restraints that have had and are
  expected to have a major impact upon the market
• Key licensing and co-development agreements in
  the gastrointestinal therapeutics market
• Inquire For Discount _at_ http//www.rnrmarketresearc
  h.com/contacts/discount?rname145683 .

4
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• Reasons to buy
• Align your product portfolio to the markets with
  high growth potential
• Develop market entry and expansion strategies by
  identifying the potential regions and therapeutic
  segments that are poised for strong growth
• Devise a more effectively tailored
  country-specific strategy through the
  understanding of key drivers and barriers in the
  gastrointestinal therapeutics market
• Develop key strategic initiatives based upon an
  understanding of key focus areas and leading
  companies
• Accelerate and strengthen your market position by
  identifying key companies for mergers,
  acquisitions and strategic partnerships
• Complete report spread across 90 pages available
  _at_ http//www.rnrmarketresearch.com/gastrointestina
  l-therapeutics-in-major-developed-markets-to-2019-
  new-drug-approvals-and-promising-pipeline-to-count
  er-declines-from-patent-expiries-market-report.htm
  l .

5
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• Few Points of Table Of Content
• Gastrointestinal Therapeutics in Major Developed
  Markets Marketed Products (Global) 25
• 3.1 Irritable Bowel Syndrome 253.2 Ulcerative
  Colitis 253.3 Crohns Disease 253.4 Key
  Marketed Products 263.4.1 Amitiza 263.4.2
  Humira 273.4.3 Remicade 283.4.4 Simponi
  293.4.5 Cimzia 303.4.6 Tysabri 31

6
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• Related Market Reports
• Cardiovascular Diseases Therapeutics in Major
  Developed Markets to 2019 Increasing Prevalence
  and Promising Novel Drugs offset Patent Cliff
  Threat
• Linaclotide Key patent, SPC, and data
  exclusivity expiry (44 country coverage)
• EpiCast Report Ulcerative Colitis Epidemiology
  Forecast to 2022
• Ophthalmology Therapeutics in Major Developed
  Markets to 2019 New Drug Approvals and
  Promising Pipeline to Trigger Shift in Treatment
  Paradigm to Combination Therapies
• Acquired Orphan Blood Diseases Therapeutics
  Market to 2019 Search for Disease Modifying
  Drugs Central to Unlocking Premium Pricing
  Potential

7
Gastrointestinal Therapeutics in Major Developed
Markets to 2019 New Drug Approvals and
Promising Pipeline to Counter Declines from
Patent Expiries

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.